Myriad Genetics Inc. held its 2025 Annual Meeting of Stockholders on June 5, 2025. During the meeting, stockholders approved an amendment to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan, increasing the aggregate number of shares of common stock available for grant by an additional 6.5 million shares. The ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved. Additionally, the election of directors Samraat S. Raha, Heiner Dreismann, PH.D., and Colleen F. Reitan was confirmed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.